1-4 of 4
Felice P. Lin, PharmD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Rapid Achievement of MR 4.5 after Switching from Imatinib (IM) to Nilotinib (NIL) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Preliminary Results from ENESTgoal

Ellen K. Ritchie, MD, Rosalind Catchatourian, MD, Rebecca B. Klisovic, MD, Michael W Deininger, MD PhD, Harry P. Erba, MD PhD, Jerald P. Radich, Michael R. Savona, MD, Ghulam Warsi, PhD, Carole S. Paley, Ilva Dautaj, Felice P. Lin, PharmD, Michael J. Mauro, MD
Journal: Blood
Blood (2015) 126 (23): 4050.
https://doi.org/10.1182/blood.V126.23.4050.4050
Published: 2015
Journal Articles

Change in Chronic Low-Grade Nonhematologic Adverse Events (AEs) and Quality of Life (QoL) in Adult Patients (pts) with Philadelphia Chromosome–Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Switched From Imatinib (IM) to Nilotinib (NIL)

Jorge E. Cortes, MD, Jeffrey H. Lipton, MD, PhD, Carole B. Miller, MD, Sikander Ailawadhi, MD, Luke Akard, MD, Javier Pinilla-Ibarz, MD, PhD, Felice P. Lin, PharmD, Solveig G. Ericson, MD, PhD, Michael J. Mauro, MD
Journal: Blood
Blood (2012) 120 (21): 3782.
https://doi.org/10.1182/blood.V120.21.3782.3782
Published: 2012
Journal Articles

Effect of Nilotinib (NIL) on Molecular Response in Chronic Myelogenous Leukemia - Chronic Phase (CML-CP) Patients (pts) with a Suboptimal Molecular Response to Imatinib (IM)–ENABL Study Update

Sikander Ailawadhi, MD, Carole B. Miller, MD, Anand P. Jillella, MD, Nebu Koshy, MD, Brian Tudor, MD, Luke P. Akard, MD, Solveig G. Ericson, MD- PhD, Felice P. Lin, PharmD, Jerald P. Radich, MD, Daniel J. DeAngelo, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 2771.
https://doi.org/10.1182/blood.V118.21.2771.2771
Published: 2011
Journal Articles

Patients (Pts) with Ph+ Chronic Myeloid Leukemia In Chronic Phase (CML-CP) with a Suboptimal Molecular Response to Imatinib (IM) Can Achieve Deeper Responses When Switched to Nilotinib

Carole Miller, MD, Sikander Ailawadhi, MD, Anand P. Jillella, MD, Jerald P. Radich, MD, Daniel J DeAngelo, MD, PhD, Stuart L Goldberg, MD, Denise Williams, MD, Felice P. Lin, PharmD, Luke Paul Akard, MD
Journal: Blood
Blood (2010) 116 (21): 2301.
https://doi.org/10.1182/blood.V116.21.2301.2301
Published: 2010